Q-omics provides the consensus-scored PLEKHH2 profile across patient tissues and cancer cell-line models. PLEKHH2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, PLEKHH2 is differentially expressed in 16, with the highest sampling consensus in KICH. Additionally, PLEKHH2 RNA expression shows 19,628 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, KICH, and THYM as cancer lineages where PLEKHH2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLEKHH2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLEKHH2 survival associations across molecular data types. PLEKHH2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLEKHH2 RNA expression–survival associations across cancer types. High PLEKHH2 expression shows unfavorable associations in ACC and STAD, but favorable associations in MESO, BRCA, SKCM and KIRC. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify MESO as the clearest survival context for PLEKHH2 RNA expression.
This table summarizes PLEKHH2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 3. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PLEKHH2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLEKHH2 shows lower tumor expression in KICH, COAD, LUAD, LUSC, BLCA and THCA. The KICH box plot shows higher PLEKHH2 RNA expression in normal versus tumor tissue (log2 FC = −3.011, t-test p < 0.001).
This table shows molecular features associated with PLEKHH2 in patient tissues and cancer cell lines. In patient samples, PLEKHH2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PLEKHH2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and SKIN.
